XM does not provide services to residents of the United States of America.
H
H

Holmen

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

JPM starts Holmen at 'underweight' on below-peers mill timber EPS growth

BUZZ-JPM starts Holmen at 'underweight' on below-peers mill timber EPS growth ** J.P.Morgan initiates Swedish paper products maker Holmen HOLMb.ST with "underweight", saying its mill timber EPS growth is the lowest among peers ** It prefers Finland's UPM UPM.HE and Stora Enso STERV.HE , considering its broadly positive mill timber view on the secto
H
J
S
U

Givaudan, National Grid, Schneider Electric

EUROPE RESEARCH ROUNDUP-Givaudan, National Grid, Schneider Electric June 18 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Givaudan, National Grid and Schneider Electric, on Tuesday. HIGHLIGHTS * Crest Nicholson Holdings Plc CRST.L : RBC raises target price to 250p from 175p * Givaudan SA GIVN.S : JP Morgan raises target price to CHF 4,200 from CHF 3,800 * National Grid NG.L : Barclays cuts target price to 1120p from 1365p * Schne
A
B
C
C
E
G
G
H
H
H
I
I
L
L
N
P
S
S
S
H
A
A
N
S
S
W

Citi upgrades Billerud on cancellation of Escanaba mill conversion

BUZZ-Citi upgrades Billerud on cancellation of Escanaba mill conversion ** Citigroup raises Billerud BILL.ST to "neutral" from "sell", saying the recent cancellation of Escanaba mill conversion improves its medium-term outlook for cashflows, utilisation rates and margins ** It expects the Swedish pulp maker's free cash flow to increase from SEK 2 b
B
H
S

Adidas, EFG International, Smith & Nephew

EUROPE RESEARCH ROUNDUP-Adidas, EFG International, Smith & Nephew May 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adidas, EFG International, and Smith & Nephew, on Thursday. HIGHLIGHTS * Adidas AG ADSGn.DE : Barclays raises target price to EUR 243 from EUR 231 * EFG International AG EFGN.S : Citigroup raises to buy from neutral * Gsk GSK.L : JP Morgan raises target price to 1660p from 1530p * Kemira Oyj KEMIRA.HE : Berenberg
3
A
A
A
C
E
E
G
H
H
H
I
K
L
M
N
P
S
T
W
A
J
P
T

AstraZeneca, Carl Zeiss Meditec, Luceco

EUROPE RESEARCH ROUNDUP-AstraZeneca, Carl Zeiss Meditec, Luceco April 5 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including AstraZeneca, Carl Zeiss Meditec and Luceco, on Friday. HIGHLIGHTS * AstraZeneca AZN.L : HSBC raises target price to 12,950p from 12,150p * Carl Zeiss Meditec AG AFXG.DE : JP Morgan raises target price to EUR 70 from EUR 59 * Ipsen SA IPN.PA : RBC raises target price to EUR 127 from EUR 124 * Luceco Plc LUCEL.L : P
A
A
A
B
B
C
E
G
H
I
K
S
S
S
S
W
A
A
A
A
A
A
B
D
S
U
Z

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.